Search





Search





Markets
/
Stocks
/
nasdaq-vtrs
/

Viatris Inc

VTRS

Add to Watchlist

17.170USD

-0.220-1.27%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

20.00BMarket Cap

LossP/E TTM



Viatris Inc

17.170

-0.220-1.27%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Viatris Inc

Currency: USD Updated: 2026-05-08

Key Insights

Viatris Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.77.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Viatris Inc's Score

Industry at a Glance

Industry Ranking

15 / 156

Overall Ranking

62 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Viatris Inc Highlights

StrengthsRisks

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

Undervalued

The company’s latest PE is -57.51, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.01B shares, decreasing 6.00% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 10.93K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

15.765

Target Price

+3.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Viatris Inc is 7.61, ranking 100 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 3.52B, representing a year-over-year increase of 8.07%, while its net profit experienced a year-over-year increase of 105.80%.

Score

Industry at a Glance

Previous score

7.61

Change



Financials

5.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.61

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Viatris Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Viatris Inc is 8.93, ranking 3 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is -57.51, which is -616.27% below the recent high of 296.91 and -354.47% above the recent low of -261.36.

Score

Industry at a Glance

Previous score

8.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 15/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Viatris Inc is 7.33, ranking 105 out of 156 in the Pharmaceuticals industry. The average price target is 13.11, with a high of 15.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

16.515

Target Price

-5.03%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Viatris Inc

VTRS

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Viatris Inc is 9.63, ranking 4 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 18.68 and the support level at 14.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.82

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.520

Buy

RSI(14)

79.619

Buy

STOCH(KDJ)(9,3,3)

90.139

Overbought

ATR(14)

0.541

High Vlolatility

CCI(14)

199.835

Buy

Williams %R

11.356

Overbought

TRIX(12,20)

0.606

Sell

StochRSI(14)

72.682

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

16.246

Buy

MA10

15.581

Buy

MA20

14.978

Buy

MA50

14.263

Buy

MA100

13.922

Buy

MA200

12.072

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Viatris Inc is 7.00, ranking 47 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 86.44%, representing a quarter-over-quarter decrease of 1.28%. The largest institutional shareholder is The Vanguard, holding a total of 134.20M shares, representing 11.53% of shares outstanding, with 6.06% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

137.69M

-1.50%

Davis Selected Advisers, L.P.

Star Investors

78.18M

+12.74%

T. Rowe Price Associates, Inc.

Star Investors

77.29M

-5.95%

BlackRock Institutional Trust Company, N.A.

62.10M

+1.54%

State Street Investment Management (US)

55.31M

-0.71%

Dimensional Fund Advisors, L.P.

40.03M

+7.11%

Geode Capital Management, L.L.C.

31.11M

+3.98%

Columbia Threadneedle Investments (US)

26.09M

-4.96%

Rubric Capital Management LP

25.50M

+65.75%

Deerfield Management Company, L.P.

20.21M

-16.15%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Viatris Inc is 8.80, ranking 21 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.